Tularemia medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 22: Line 22:
[[Category:Biological weapons]]
[[Category:Biological weapons]]
[[Category:Infectious disease]]
[[Category:Infectious disease]]
[[Category:Needs overview]]

Revision as of 22:24, 10 December 2012

Tularemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Tularemia from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Findings

Treatment

Medical Therapy

Prevention

Case Studies

Case #1

Tularemia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tularemia medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tularemia medical therapy

CDC on Tularemia medical therapy

Tularemia medical therapy in the news

Blogs on Tularemia medical therapy

Directions to Hospitals Treating Tularemia

Risk calculators and risk factors for Tularemia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Medical Therapy

The drug of choice is Streptomycin.[1] Tularemia may also be treated with gentamicin, tetracycline, chloramphenicol or fluoroquinolones.

  • In a contained casualty setting, where individual patient management is possible, the working group recommends parenteral antimicrobial therapy. Streptomycin is the drug of choice. Gentamicin, which is more widely available and can be used intravenously, is an acceptable alternative. Treatment with aminoglycosides should be continued for 10 days. Tetracyclines and chloramphenicol are also used, but relapses and primary treatment failures occur at a higher rate with these bacteriostatic agents than with aminogylcosides, and they should be given for at least 14 days to avoid relapse. Both streptomycin and gentamicin are recommended as first-line treatment of tularemia in children.
  • In a mass casualty setting, doxycycline and ciprofloxacin, administered orally, are the preferred choices for treatment of both adults and children. As described in the table below, 'Treatment with ciprofloxacin should be continued for 10 days; treatment with doxycycline should be continued for 14-21 days.'
  • Since it is unknown whether drug-resistant organisms might be used in a bioterrorist event, antimicrobial susceptibility testing of isolates should be conducted quickly and treatments altered according to test results and clinical responses.
  • Antibiotics for treating patients infected with tularemia in a bioterrorist event are included in the national pharmaceutical stockpile maintained by CDC, as are ventilators and other emergency equipment.[2][3]
Working Group Consensus Recommendations for Treatment of Patients With Tularemia

References

  1. Enderlin G, Morales L, Jacobs RF, Cross JT (1994). "Streptomycin and alternative agents for the treatment of tularemia: review of the literature". Clin Infect Dis. 19: 42&ndash, 7.
  2. http://www.bt.cdc.gov/agent/tularemia/facts.asp
  3. http://www.bt.cdc.gov/agent/tularemia/tularemia-biological-weapon-abstract.asp#2

Template:WH Template:WS